IL-11 Cysteine Variants PEGylation for Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein therapeutics, such as interleukin-11 (IL-11), have short circulating half-lives, requiring frequent injections and leading to fluctuating concentrations, which can result in decreased efficacy and increased adverse effects due to rapid clearance, making them costly and inconvenient for patients and healthcare providers.
Innovation Solution
Development of cysteine variants of IL-11 with added non-native cysteine residues and modification with polyethylene glycol (PEG) to extend the protein's half-life, allowing for less frequent administration and improved stability and solubility, using methods like site-specific conjugation with cysteine-reactive PEGs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If protein therapeutics are administered by injection, then they can be delivered to the body, but they are cleared rapidly from the body requiring frequent injections
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of the protein therapeutic through PEGylation. By attaching polyethylene glycol chains to the protein, the hydrodynamic radius increases, the protein becomes more hydrophilic, and the renal clearance rate decreases. This parameter modification extends the circulating half-life from hours to days, reducing injection frequency while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates a composite material by combining the protein therapeutic with polyethylene glycol polymers. This composite structure consists of the active protein component and the inert PEG component, where the PEG acts as a protective shell that reduces immunogenicity and extends circulation time. The composite material approach allows the protein to retain its biological activity while gaining improved pharmacokinetic properties.
2Duration of action of moving object
If proteins are glycosylated to extend half-life, then circulating time increases, but production costs increase due to expensive mammalian cell systems
Solution Approach 1:
The patent extracts the glycosylation function from the complex mammalian cell system and replaces it with a simpler chemical modification approach. Instead of relying on cellular machinery to add sugar moieties, the invention uses PEGylation chemistry to achieve similar half-life extension effects. This extraction of the essential function (half-life extension) from the expensive production system enables cost-effective manufacturing while maintaining the desired pharmacokinetic properties.
Solution Approach 2:
The patent substitutes a chemical modification system (PEGylation) for the biological system (mammalian cell glycosylation). By replacing the complex biological machinery required for glycosylation with a straightforward chemical conjugation process, the invention achieves comparable half-life extension at significantly lower production costs. The chemical PEGylation process can be performed in simpler expression systems like E. coli or yeast, eliminating the need for expensive mammalian cell cultures.
3Productivity
If rapid clearance of proteins occurs, then manufacturing is simpler, but the amount of protein required per patient increases dramatically
Solution Approach 1:
The patent ensures continuity of useful action by extending the protein's circulating half-life through PEGylation. The modified protein maintains therapeutic concentrations in the bloodstream for extended periods, providing continuous pharmacological effect. This continuous presence eliminates the need for repeated high-dose administrations, thereby reducing the total quantity of protein required per patient over the treatment course while maintaining productivity and therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cysteine variants of IL-11 demonstrate prolonged circulating half-lives, improved stability, and enhanced therapeutic efficacy, reducing the frequency of injections and associated costs while maintaining biological activity, thus providing a more effective and user-friendly protein therapeutic option.
Implementation Method 1
modification with polyethylene glycol (PEG) to extend the protein's half-life, allowing for less frequent administration and improved stability and solubility, using methods like site-specific conjugation with cysteine-reactive PEGs
Data Source
AI summary
Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.